Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model
Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…Salivary α-synuclein in Parkinson’s disease – a pilot study
Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the…The Synuclein-One Study: Detection of Cutaneous Phosphorylated alpha-synuclein for the Diagnosis of the Synucleinopathies
Objective: The Synuclein-One study is an NIH-funded 30-site, multicenter trial of 428 patients with synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple…Protective effect and mechanism of TREM2 in Parkinson’s disease with cognitive impairment
Objective: this study explored whether TREM2 plays a protective role in PD with cognitive impairment by promoting the activation of DAM. Background: The latest research…Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies
Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.…Distinct characteristics of gut microbiome in patients with Parkinson’s disease according to the presence of premotor REM sleep behavior disorders
Objective: We aimed to investigate whether the composition and function of gut microbiome obtained from shotgun metagenomic sequencing are different between Parkinson’s disease (PD) patients…A multicenter, matched case-control study of alpha-synuclein accumulation in the gastrointestinal tract of Parkinson’s disease
Objective: 1) To determine the possibility as a pathologic biomarker of alpha-synuclein (AS) accumulation in the gastrointestinal (GI) tract in patients with Parkinson’s disease (PD) and…Small Molecule Inhibitors for Precise Inhibition of α-Synuclein Oligomer Generation in Parkinson’s Disease (PD)
Objective: To develop small molecule therapeutics for PD that inhibit production of toxic α-synuclein oligomers and reduce aggregate formation, targeting the molecular mechanisms at the…Recruiting people at risk of Parkinson’s disease: comparative data from PPMI Online and HeBA Kassel
Objective: To compare a US- and Germany-based staged screening process to identify people at risk of developing Parkinson’s disease (PD). Background: The Parkinson’s Progression Marker…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 60
- Next Page »